Clinical evidence shows that AposHealth (an FDA-cleared medical device) improves pain, stiffness, and function in people with knee osteoarthritis.

By HEOR Staff Writer

April 21, 2023

However, it’s uncertain if these improvements are clinically meaningful. The analyses suggest that AposHealth is cost saving by £1,958 per person when compared with standard care if knee surgery is delayed for 5 years. Because the evidence for the potential cost savings is limited, further data collection is recommended to understand if cost savings are made once AposHealth is used in the NHS.

Reference url

Recent Posts

Promising PSMA-Targeted Therapy Delays Prostate Cancer Progression

By HEOR Staff Writer

October 20, 2025

Novartis recently announced pivotal data from the Phase III PSMAddition trial. It demonstrates that PSMA-targeted therapy with Pluvicto™ (lutetium-177 vipivotide tetraxetan) combined with standard of care (androgen receptor pathway inhibitor plus androgen deprivation therapy) significantly reduce...
Cabotegravir HIV Prevention: First Injectable PrEP Recommended for High-Risk Groups

By HEOR Staff Writer

October 17, 2025

Cabotegravir HIV prevention is now officially recommended in the UK for adults and young people at high risk of HIV who cannot take daily oral PrEP. What makes this approval so significant? For those unable to adhere to daily medication, cabotegravir provides a bi-monthly injectable alternative w...
Social Media Policy Action: Protecting Youth from Cognitive Risks

By João L. Carapinha

October 16, 2025

A recent editorial published in JAMA emphasizes the urgent need for social media policy action due to the developmental impacts of social media on youth. The article discusses a pivotal study by Nagata et al., which examined a large cohort of adolescents. This study revealed that increas...